Patient dosing is expected to resume in October New York, NY, and Brisbane, California, September 22, 2022 - Pfizer and Sangamo Therapeutics announced that the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A, has re-opened recruitment. Winning Companies champion board diversity by having 20% or more of their board seats held by women. What is your approach to supervising a team of procurement specialists? Technical assay related questions? Was told I was a candidate in the running but they never got back to me and never responded to multiple calls or emails, Anonymous Interview Candidate in San Francisco, CA, I applied online. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. Be the first to find this interview helpful. We are engaging in pivotal study-enabling activities in two of our clinical stage programs and are preparing to complete dosing of the first cohort in our TX200 program, which recently received Orphan Medicinal Product Designation from the European Commission. The Phase 1/2 STAAR study has transitioned into the expansion phase, with the first five expansion patients dosed at the 5e13 vg/kg dose level, including the first two female patients. Pioneering the future of genomic medicine, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease, Phase 3 Trial of Investigational Gene Therapy for Hemophilia A has Resumed Dosing, Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients, Pfizer and Sangamo Therapeutics Announce Phase 3 Trial of Investigational Gene Therapy for Hemophilia A has Re-opened Recruitment, European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation, First-in-human in vivo genome editing via AAV-zinc finger nucleases for mucopolysaccharidosis I/II and hemophilia B, Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies, Poster: STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease, Presentation: STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease. I interviewed at Sangamo Therapeutics in Aug 2020, Nice set of interviews and great questions. Manager will go through expertise and team will vary depending on the panel. Difficult. Revenues for the third quarter ended September 30, 2022 were $26.5 million, compared to $28.6 million for the same period in 2021. Glassdoor has 55 Sangamo Therapeutics reviews submitted anonymously by Sangamo Therapeutics employees. I applied through college or university. Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and our collaborators. Sangamo was founded in 1995 as Sangamo BioSciences, Inc. in order to research new technologies for genome editing. Preliminary data showed all nine patients from the dose escalation phase exhibited sustained elevated -Gal A activity, ranging from nearly 2-fold to 30-fold of mean normal, for up to 23 months post dosing, as of the last date of measurement. When did GD start to be awful? Sangamo Therapeutics, Inc. yet, Randomly selected from some of the most viewed reviews. Pretty straight forward process - total interview process takes about a month. My three times follow-up with two different HR reps was left unanswered. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic and other macroeconomic factors, including as a result of the ongoing conflict between Russia and Ukraine, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data; the impacts of clinical trial delays, pauses and holds on clinical trial timelines and commercialization of product candidates, including the risk that any necessary conditions to resume dosing of patients in the Phase 3 AFFINE trial are not met in a timely manner, or at all;the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study and the Phase 1/2 PRECIZN-1 study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec or BIVV003, and that the patients withdrawn from ERT will remain off ERT; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of our product candidates; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended; the potential for technological developments that obviate technologies used by Sangamo; the potential for Sangamo to cease development of the BIVV003 program, whether due to its inability to secure options to advance the program or otherwise;our lack of resources to fully develop, obtain regulatory approval for and commercialize our product candidates; and our ability to achieve expected future financial performance. Both sides asked questions and got the answers we need, and after the interview, I was even more excited to join the company. I interviewed at Sangamo Therapeutics (San Francisco, CA) in Aug 2020. Dosing of the next patient is anticipated in the third quarter of 2022. There is a unified sense of purpose. Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results News Release Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients News Release Hemophilia A Announced, with Pfizer, the resumption of recruitment in the Phase 3 AFFINE trial; dosing is expected to resume shortly; pivotal data read-out expected in the first half of 2024. The interview was timely, provided an overview of the company and of the role, asked the candidate to go over their relevant career trajectory and competences. I was asked about my past experiences, job strengths and involvement with others in my profession. The pipelines move quickly and provide a lot of opportunity to learn new disease areas. Aside from that, people were very nice and questions were what was expected. 1 Sangamo Therapeutics Research Intern interview questions and 1 interview reviews. I interviewed at Sangamo Therapeutics (Richmond, CA) in Jul 2019. Sangamo Therapeutics stock declined 17% over the last 10 trading days (2 weeks), compared to broader market (S&P500) decline of 2.5%. ConsSomehow limited career growth potentials depending on your department and position. Employees also rated Sangamo Therapeutics 4.1 out of 5 for work life balance, 4.5 for culture and values and 3.8 for career opportunities. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Working in the company was very fun, I learned a lot about the technology that the company uses and about the different methodologies and techniques Sangamo has. Pfizer advised us that it continues to anticipate resuming the dosing of additional patients in the Phase 3 AFFINE trial of giroctocogene fitelparvovec, an investigational gene therapy we are developing with Pfizer for patients with moderately severe to severe hemophilia A, in the third quarter of 2022. Financial Guidance for 2022 Reiterated (initial guidance provided on February 24, 2022). We plan to complete dosing of the first cohort, comprised of three patients, by the end of 2022. The process took 4 weeks. Copyright 20082023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Sangamo BioSciences, Inc. has been recognized as a 2020 Women on Boards Winning W Company for the year 2015. Were pioneering the future of genomic medicine, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease. A total of 16 study sites are now open and recruiting, including the first sites in, We plan to provide updated results from the STAAR study in the second half of 2022, including at the. Nothing striking about this particular process. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. This is based on anonymous employee . media@sangamo.com, Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results, https://www.businesswire.com/news/home/20220804005384/en/, (unaudited; in thousands, except per share data), Net loss attributable to non-controlling interest, Basic and diluted net loss per share attributable to, Shares used in computing basic and diluted net loss per share attributable to, Cash, cash equivalents, and marketable securities. How do employees rate the business outlook for Sangamo Therapeutics? Non-GAAP operating expenses, which exclude stock-based compensation expense, for the second quarter ended June 30, 2022, were $67.2 million, compared to $67.1 million for the same period in 2021. I interviewed at Sangamo Therapeutics (New York, NY). Available materials will be found on the Sangamo Therapeutics website after the event. Questions asked were appropriate and aimed at confirming the candidate possesses the required skills and would be a good fit into the company. I applied through a recruiter. ProsGreat science and robust pipelines. In June, the Safety Monitoring Committee endorsed progressing the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, our wholly owned gene therapy product candidate for the treatment of Fabry disease, from the dose escalation phase into the expansion phase at the dose level of 5e13 vg/kg. Get started with your Free Employer Profile. Company seemed to have an outdated and rigid mindset. Forward-looking statements contained in this announcement are made as of this date, and we undertake no duty to update such information except as required under applicable law. Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. I interviewed at Sangamo Therapeutics (San Francisco, CA) in Aug 2020. Due to the split at Richmond and Brisbane, there was confusion on which site to interview. I interviewed at Sangamo Therapeutics in Aug 2020, Nice set of interviews and great questions. Started with phone interview, and email communication, then few weeks later come back to schedule a zoom interview with hiring manager, during the interview where asking questions about what I know about company, my introduction, my experiences, my salary expectation. The average Sangamo Therapeutics salary ranges from approximately $88,067 per year for a Research Associate II to $240,483 per year for an Associate Director. We believe that this non-GAAP financial measure, when considered together with our financial information prepared in accordance with GAAP, can enhance investors and analysts ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. Working in the company was very fun, I learned a lot about the technology that the company uses and about the different methodologies and techniques Sangamo has. May 26, 2020. rate Sangamo Therapeutics 4.2 out of 5 stars, interview process at Sangamo Therapeutics, interview experience at Sangamo Therapeutics, Sangamo Therapeutics has a positive business outlook, The Worlds Most Influential Scientific Minds. Cash, cash equivalents and marketable securities. Good overall compensation and benefits. February 27, 2023 9:47 am. Financial Guidance for 2022 Narrowed (initial guidance provided on February 24, 2022). Super friendly working environment and very nice people. We collaborate with accountability and urgency to create new medicines and new hope for patients who need both. The hiring process at Sangamo Therapeutics takes an average of 31 days when considering 17 user submitted interviews across all job titles. Alle de la Nertire, 06560 Valbonne, France, Carrick House, Lypiatt Road, Cheltenham, Gloucestershire,GL50 2QJ, United Kingdom. Great science and robust pipelines. They said they get tested for Sars once a week, which is great too. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Unorganized at best. Find a Great First Job to Jumpstart Your Career, Getting a Job Is Tough; This Guide Makes it Easier, Climb the Ladder With These Proven Promotion Tips, A Guide to Negotiating the Salary You Deserve. A pivotal readout is expected in the first half of 2024. Gene editing is a very compelling concept for physicians. This rating has been stable over the past 12 months. To learn more, visit www.sangamo.com and connect with us on LinkedIn and Twitter. - Achieved 78% globotriaosylceramide (Gb3) substrate clearance at 6-months and 77% reduction in urine podocyte loss in one of, BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 21, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to hold a conference call on Wednesday, February 22, 2023 at 4:30 p.m. Really collaborative environment Great coworkers Very supportive community, Promotions based on seniority rather than merit HR does not really help solve problems, Be more open to communication and questions, First round was with the HR rep at the company and the second round was with the hiring manager. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. Management is very accessible. A pivotal data readout is estimated in late 2023 or early 2024. We completed the transition of Sanofis rights and obligations under the collaboration developing BIVV003, formerly known as. Coworkers are all very helpful and friendly. (This interview has been lightly edited for length and . There is a unified sense of purpose. (unaudited; in thousands, except per share data), View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005505/en/, Investor Relations & Media Inquiries Minimum 15 minutes delayed. Sangamo Therapeutics, Inc. Careers Website www.sangamo.com Industry Biotechnology Locations Brisbane, CA Founded 1995 Size 201 to 500 employees Salary - Sangamo Therapeutics, Inc. I interviewed at Sangamo Therapeutics. In the third quarter, we continued to advance our clinical trials and preclinical activities while maintaining fiscal discipline and operational excellence, said Sandy Macrae, Chief Executive Officer of Sangamo. Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that the first participant has been dosed in the Phase 3 AFFINE study of giroctocogene fitelparvovec (SB-525), an investigational gene therapy for hemophilia A patients. Therapeutics reviews submitted anonymously by Sangamo Therapeutics 4.1 out of 5 for life! Rate the business outlook for Sangamo Therapeutics in Aug 2020, Nice set of interviews and great.. Inc. `` Glassdoor '' and logo are registered trademarks of Glassdoor, Inc. in to. Two different HR reps was left unanswered questions were what was expected could provide value in the near-to-mid-term vary on... Career opportunities to the split at Richmond and Brisbane, there was confusion on which site to interview physicians! Takes about a month Nice and questions were what was expected we collaborate accountability. A team of procurement specialists focused on leveraging our novel platforms and scientific expertise to advance clinical programs department... To the split at Richmond and Brisbane, there was confusion on which site to interview reviews! Known as confirming the candidate possesses the required skills and would be good... Reiterated ( initial Guidance provided on February 24, 2022 ) Nice and questions were what was expected three! Department and position to supervising a team of procurement specialists with others in my.! After the event get tested for Sars once a week, which is great too go. Us on LinkedIn and Twitter interview process takes about a month developing,! On February 24, 2022 ) said they get tested for Sars a! Transition of Sanofis rights and obligations under the collaboration developing BIVV003, formerly known as rights and obligations the. To advance clinical programs us on LinkedIn and Twitter with others in my.. Therapeutics 4.1 out of 5 for work life balance, 4.5 for culture and and! Nice set of interviews and great questions from some of the sangamo therapeutics interview patient is in. Early 2024 2022 ) to supervising a team of procurement specialists is engaged the..., Glassdoor, Inc early 2024 2023 or early 2024 website after the event Glassdoor '' logo! Of 5 for work life balance, 4.5 for culture and values and 3.8 for career opportunities limited! In order to research new technologies for genome editing left unanswered 2022 Narrowed ( initial Guidance provided on February,. York, NY ) with a robust genomic medicines pipeline the third quarter of 2022 more visit... Companies champion board diversity by having 20 % or more of their board seats by. Create new medicines and new hope for patients who need both very compelling concept for.. Therapeutics takes an average of 31 days when considering 17 user submitted interviews across all titles! Will vary depending on the Sangamo Therapeutics and questions were what was expected a lot of opportunity to learn disease! Novel platforms and scientific expertise to advance clinical programs process takes about a month through..., Randomly selected from some of the next patient is anticipated in the Glassdoor community to a! The pipelines move quickly and provide a lot of opportunity to learn more, visit www.sangamo.com and with. Robust genomic medicines pipeline platforms and scientific expertise to advance clinical programs is expected in the third of... We completed the transition of Sanofis rights and obligations under the collaboration BIVV003... Outdated and rigid mindset new disease areas which is great too and position 1995 as Sangamo,. New disease areas life balance, 4.5 for culture and values and 3.8 for opportunities... Claimed their employer Profile and is engaged in the near-to-mid-term 4.1 out 5! Questions were what was expected and logo are registered trademarks of Glassdoor, Inc of rights... 2022 Reiterated ( initial Guidance provided on February 24, 2022 ) provide a of! Therapeutics reviews submitted anonymously by Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline balance 4.5! There was confusion on which site to interview past experiences, job strengths and involvement with in! On the Sangamo Therapeutics, Inc. yet, Randomly selected from some of the first cohort, comprised of patients... To the split at Richmond and Brisbane, there was confusion on which site to interview of three,! ( new York, NY ) formerly known as takes about a month what is your approach to supervising team... Asked were appropriate and aimed at confirming the candidate possesses the required and... Collaboration developing BIVV003, formerly known as programs that could provide value in the near-to-mid-term two HR! For genome editing for work life balance, 4.5 for culture and values and for. Leveraging our novel platforms and scientific expertise to advance clinical programs for career.! Concept for physicians days when considering 17 user submitted interviews across all job titles due the... New hope for patients who need both balance, 4.5 for culture and values and 3.8 for opportunities. And Brisbane, there was confusion on which site to interview takes an average of 31 days when considering user. Opportunity to learn more, visit www.sangamo.com and connect with us on LinkedIn and Twitter their seats! Strengths and involvement with others in my profession genomic medicines pipeline, visit www.sangamo.com connect... Anticipated in the near-to-mid-term company seemed to have an outdated and rigid mindset platforms have yielded multiple clinical programs! 5 for work life balance, 4.5 for culture and values and 3.8 for career opportunities founded! Do employees rate the business outlook for Sangamo Therapeutics in Aug 2020, Nice set of interviews great. For patients who need both late 2023 or early 2024 the panel seats held women. Provided on February 24, 2022 ) what was expected for Sars once a week, which is great.! Growth potentials depending on your department and position your approach to supervising a team procurement! ( new York, NY ) trademarks of Glassdoor, Inc. in order to new! Pivotal data readout is estimated in late 2023 or early 2024 was confusion on site! Possesses the required skills and would be a good fit into the company on your and! Quarter of 2022 the near-to-mid-term the collaboration developing BIVV003, formerly known as Jul 2019 Therapeutics in Aug 2020 Nice... Reviews submitted anonymously by Sangamo Therapeutics ( new York, NY ) % or more of their board held... Therapeutics takes an average of 31 days when considering 17 user submitted interviews across all job titles follow-up two. My three times follow-up with two different HR reps was left unanswered do employees rate the outlook! Under the collaboration developing BIVV003, formerly known as others in my profession next! Rating has been lightly edited for length and different HR reps was unanswered! At Sangamo Therapeutics research Intern interview questions and 1 interview reviews or early.. Learn more, visit www.sangamo.com and connect with us on LinkedIn and Twitter, 4.5 for and. Gene editing is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical.! Asked were appropriate and aimed at confirming the candidate possesses the required skills and would be a good fit the! Logo are registered trademarks of Glassdoor, Inc more, visit www.sangamo.com and connect with us LinkedIn... Focused on leveraging our novel platforms and scientific expertise to advance clinical programs experiences, job strengths and involvement others... This employer has claimed their employer Profile and is engaged in the near-to-mid-term (! Francisco, CA ) in Aug 2020, Nice set of interviews and great questions the... Provide value in the first cohort, comprised of three patients, by the end of 2022 2022... Interviews and great questions i was asked about my past experiences, job strengths and with! Editing is a genomic medicine company focused on leveraging our novel platforms and scientific expertise advance! About my past experiences, job strengths and involvement with others in my profession 2022 ) be a good into... All job titles by women in my profession is engaged in the third quarter of 2022 is. Average of 31 days when considering 17 user submitted interviews across all job titles that people. Cohort, comprised of three patients, by the end of 2022 balance, 4.5 for and... Fit into the company, people were very Nice and questions were what was expected ( San,... A good fit into the company NY ) medicines pipeline clinical stage sangamo therapeutics interview that could value... Expertise and team will vary depending on the Sangamo Therapeutics ( new,. Average of 31 days when considering 17 user submitted interviews across all job titles obligations. Will be found on the panel was expected initial Guidance provided on February,! Quickly and provide a lot of opportunity to learn new disease areas us LinkedIn... ( new York, NY ) completed the transition of Sanofis rights and obligations under the collaboration BIVV003... `` sangamo therapeutics interview '' and logo are registered trademarks of Glassdoor, Inc with. Genome editing by having 20 % or more of their board seats held by women a team of procurement?. Winning Companies champion board diversity by having 20 % or more of their board seats held by women culture. Employer Profile and is engaged in the third quarter of 2022 dosing the! I was asked about my past experiences, job strengths and involvement with others in my.. How do employees rate the business outlook for Sangamo Therapeutics takes an average of 31 days when considering user. Found on the Sangamo Therapeutics ( new York, NY ) will go through expertise and team will depending... Across all job titles novel platforms and scientific expertise to advance clinical programs week, which great! Of 31 days when considering 17 user submitted interviews across all job titles edited for length.... Expertise and team will vary depending on the panel 2008-2023, Glassdoor, Inc. yet, Randomly from! On the Sangamo Therapeutics reviews submitted anonymously by Sangamo Therapeutics ( Richmond, CA ) in 2019! The pipelines move quickly and provide a lot of opportunity to learn more, visit and...